Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity Purpose of Review The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. Recent Findings Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended. There is no recommendation regarding testing in adults. Summary There is clear evidence pointing to the role of pharmacogenetics and pharmacogenomics in cardiotoxicity suscepti- bility to chemotherapeutic agents. Larger scale studies are needed to further identify susceptibility markers and to develop pharmacogenomics-based risk profiling to improve quality of life and life expectancy in cancer survivors. . . . Keywords Chemotherapy-induced cardiomyopathy Chemotherapy-induced cardiotoxicity Pharmacogenetics of cancer Pharmacogenomics of cancer Introduction are living longer, these cardiotoxicity effects are becoming increasingly recognized and cardio-oncology is emerging as Despite recent advances in cancer treatment, cardiotoxicity a multidisciplinary field to advance our ability to diagnose, can result from traditional chemotherapy agents such as treat, and prevent these potentially devastating side effects. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity

Loading next page...
 
/lp/springer_journal/pharmacogenetics-of-chemotherapy-induced-cardiotoxicity-SKJB00TY6j
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
D.O.I.
10.1007/s11912-018-0696-8
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. Recent Findings Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended. There is no recommendation regarding testing in adults. Summary There is clear evidence pointing to the role of pharmacogenetics and pharmacogenomics in cardiotoxicity suscepti- bility to chemotherapeutic agents. Larger scale studies are needed to further identify susceptibility markers and to develop pharmacogenomics-based risk profiling to improve quality of life and life expectancy in cancer survivors. . . . Keywords Chemotherapy-induced cardiomyopathy Chemotherapy-induced cardiotoxicity Pharmacogenetics of cancer Pharmacogenomics of cancer Introduction are living longer, these cardiotoxicity effects are becoming increasingly recognized and cardio-oncology is emerging as Despite recent advances in cancer treatment, cardiotoxicity a multidisciplinary field to advance our ability to diagnose, can result from traditional chemotherapy agents such as treat, and prevent these potentially devastating side effects.

Journal

Current Oncology ReportsSpringer Journals

Published: Apr 30, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off